Monitor for future Form 4 filings by McDevitt reflecting any open-market purchases or sales, which would provide clearer signals on insider conviction. The amended vesting schedule on the 387,063-share option suggests a retention-focused compensation adjustment.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Oct 29 $14.89entry
- T+1 · 6d ago −12.42%α −11.95% · $13.04
- T+5 · due 11h ago Pending
- T+5 · todayOpen
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Damien McDevitt, President and CEO of Aspen Neuroscience, filed an initial statement of beneficial ownership (Form 3) disclosing 485,751 shares of common stock held directly through a family trust, plus additional shares held through three irrevocable trusts, and two stock option grants (one fully vested, one with amended vesting schedule). The filing is a routine insider ownership disclosure with no material financial impact.
Key Facts
- Damien McDevitt filed Form 3 as President and CEO of Aspen Neuroscience, Inc.
- McDevitt directly holds 485,751 shares of common stock through the Marnell-McDevitt Family Trust, of which 93,607 shares remain subject to performance-based vesting and repurchase conditions.
- McDevitt also holds 25,299 shares in each of three irrevocable trusts (Finn, Aran, Conor McDevitt 2025 Irrevocable Trusts).
- McDevitt holds a fully vested option to buy 196,820 shares at $8.70, expiring December 15, 2034.
- McDevitt holds an option to buy 387,063 shares at $5.74, originally vesting over 48 months from December 2025, amended in August 2026 to vest in equal monthly installments through November 20, 2031.
- The filing includes a Power of Attorney authorizing Jeffrey L. Boerneke, Leslie A. Brault, and Janet Katz to act on McDevitt's behalf for SEC filings.
Financial Impact
No financial impact; routine ownership disclosure with no transaction or change in holdings.
Risk Factors
- No material risks identified from this routine filing.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-439047 |
| Document: 0001193125-26-439047-index-headers.html | 0001193125-26-439047 |
| Document: 0001193125-26-439047-index.html | 0001193125-26-439047 |
| Document: 0001193125-26-439047.txt | 0001193125-26-439047 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 2d ago | SC 13G | $12.29 $12.76 | ▲ +3.82% | ▲ +2.17% | $11.76 (−4.31%) |
Nov 2, 2026 2d ago | Insider Cluster | $12.29 $12.76 | ▲ +3.82% | ▲ +2.17% | $11.76 (−4.31%) |
Nov 2, 2026 2d ago | Insider Cluster | $12.29 $12.76 | ▲ +3.82% | ▲ +2.17% | $11.76 (−4.31%) |
Nov 2, 2026 3d ago | 8-K | $12.29 $12.76 | ▲ +3.82% | ▲ +2.17% | $11.76 (−4.31%) |
Oct 30, 2026 6d ago | 424B4 | $13.04 $12.29 | ▼ −5.75% | ▼ −6.05% | $11.76 (−9.82%) |
Oct 30, 2026 6d ago | EFFECT | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
Oct 29, 2026 6d ago | Press Release | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
Oct 29, 2026 6d ago | 3 | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
Oct 29, 2026 6d ago | 3 | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
Oct 29, 2026 6d ago | 3 | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers